Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"

Cure51

Publication Date:
Feb 10, 2026

In a recent feature on Europe 1’s La France Bouge, Cure51's CEO and co-founder Nicolas Wolikow shared compelling insights into the company’s groundbreaking approach to understanding Cancer survival.

Cure51’s mission is simple yet revolutionary: unlock the biological secrets of exceptional Cancer survivors and use that knowledge to transform future Cancer treatments.

Credit: Europe 1

Updated: February 18, 2026

Table of Contents

NEWS